Immunotherapy has helped some young people with alveolar soft part sarcoma (ASPS), a rare cancer, but there’s more work to be done.

by Kyle Bagenstose

The FDA requires a warning with CAR T-cell therapies about an increased risk of cancer from the treatment. Should you be concerned?

by Sandra Gordon

Immunotherapy before surgery is proving to be an effective treatment against melanoma.

by Sandra Gordon

Cancer survivor Laurie Adami reflects on her experience participating in a clinical trial that ultimately contributed to the March 2021 approval of a CAR-T cell therapy for follicular lymphoma.

by Laurie Adami

At a patient advocate event, researchers discussed how to extend the benefits of immunotherapy to more people.

by Kevin McLaughlin

For people with melanoma who receive immune checkpoint inhibitors after surgery, side effects can remain even after treatment has been completed. These chronic side effects are most often mild.

by Anna Goshua

In recent months, drugmakers have announced they are withdrawing indications for four immune checkpoint inhibitors in consultation with the Food and Drug Administration. What does this mean for patients who are taking these drugs?

by Anna Goshua

Scientists and physicians discussed advances in targeted therapies and immunotherapies, as well as the lessons COVID-19 research has taught to cancer researchers.

by Kevin McLaughlin

Two immune checkpoint inhibitors are now approved for treatment of some people with advanced breast cancer, but trial results have raised some questions.

by Anna Goshua

The Food and Drug Administration approved an immunotherapy drug for tumors with high tumor mutational burden regardless of tumor type. But some medical oncologists say it's not clear the biomarker is valid across all cancer types.

by Anna Azvolinsky